A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions

Liver DiseasesDigestive System Diseases

Interventions

DRUG

Ozanimod

Trial Locations (3)

Orlando Clinical Research Center OCRC, Orlando

University of Miami Miller School of Medicine, Miami

The Texas Liver Institute, San Antonio